Da­ta do not sup­port wide­spread Covid vac­cine boost­ers right now, out­go­ing FDA lead­ers write in the Lancet

Last year
FDA+
Coronavirus

Ab­b­Vie dives deep­er in­to eye care, pay­ing $370M cash — with a $1.4B sweet­en­er — to part­ner on VEGF gene ther­a­py

Last year
Deals

Sanofi places new $1.9B bet even as its last sours; Sam Wak­sal's new biotech ideas; Cell ther­a­py time for Roche; and more

Last year
Weekly

Boehringer In­gel­heim taps a pop­u­lar an­ti­body dis­cov­ery play­er for ac­cess to drug 'li­brary of li­braries'

Last year
Deals

In a first, FDA warns a re­searcher for fail­ing to sub­mit da­ta 3 years af­ter tri­al com­ple­tion

Last year
FDA+

Af­ter decade-plus of fail­ures, As­traZeneca fi­nal­ly gets a win for sto­ried im­munother­a­py (kind of)

Last year
R&D

Bio­gen CEO Vounatsos laments 'con­fu­sion' and 'mis­in­for­ma­tion' lead­ing to chal­lenges with Aduhelm up­take

Last year
Pharma

Ther­mo Fish­er, as part of glob­al ex­pan­sion plans, out­lines new sin­gle-use site in Nashville

Last year
Manufacturing

Jen­nifer Doud­na's di­ag­nos­tic spin­out rais­es Mam­moth round as it ex­pands to ther­a­pies

Last year
Financing
Cell/Gene Tx

Medicx­i's mega-start­up Centes­sa rolls out first da­ta for he­mo­phil­ia drug with plans to charge ahead in­to piv­otal test

Last year
R&D

The Tachi Ya­ma­da lega­cy tree con­tin­ues to grow with a new gene edit­ing biotech from Jim Wil­son

Last year
Financing
Startups

A top pick in Paul Hud­son's cam­paign to re­vive the pipeline at Sanofi blows up in PhI­II

Last year
R&D

Top bio­phar­ma ex­ecs of­fer scare tac­tics and mixed mes­sages on drug pric­ing bills mak­ing their way to Capi­tol Hill

Last year
R&D
Pharma

One of Tachi's new­ly born lega­cy biotechs rais­es $135M and en­lists an A-list board to ad­vance late-stage vac­cine

Last year
Financing

Sanofi picks up Kad­mon and its trans­plant drug in $1.9B buy­out, giv­ing Sam Wak­sal 2 Big Phar­ma buy­outs un­der his belt

Last year
Deals

Macro­Gen­ics flips over an OS dud for can­cer drug Mar­gen­za in sur­pris­ing turn­around from ear­li­er da­ta

Last year
R&D

UK unions lam­bast plan for ma­jor lay­offs at MHRA as Brex­it takes its toll

Last year
People
Pharma

Mov­ing on from a ma­jor set­back, Roche lines up a new Hunt­ing­ton's pro­gram for gene ther­a­py sub Spark

Last year
Deals
R&D

Can­cer gi­ant Roche splash­es in­to cell ther­a­py with $3B+ Adap­ti­m­mune deal for off-the-shelf drugs

Last year
Deals
Cell/Gene Tx

Liv­er tu­mors in an­i­mals trig­ger clin­i­cal hold for Bio­Marin gene ther­a­py — high­light­ing a re­cur­ring con­cern

Last year
Cell/Gene Tx
FDA+

White House seeks $65B to pre­pare for fu­ture pan­demics in 'Apol­lo'-like ef­fort

Last year
Pharma
Coronavirus

Abrupt FDA ex­its spark con­cern; Un­pack­ing key con­cepts at gene ther­a­py sum­mit; 20 lu­mi­nar­ies who re­shaped R&D; and more

Last year
Weekly

Eli Lil­ly sued by for­mer em­ploy­ees al­leg­ing age dis­crim­i­na­tion, cit­ing hir­ing prac­tices fa­vor­ing in­terns

Last year
Pharma

Pri­vate eq­ui­ty, sov­er­eign wealth fund al­ly on an $8B buy­out aimed at tak­ing rare dis­ease play­er pri­vate

Last year
Deals
First page Previous page 112113114115116117118 Next page Last page